MO-BENSON-HILL
18.1.2023 13:01:35 CET | Business Wire | Press release
Benson Hill, Inc. (NYSE: BHIL, the “Company” or “Benson Hill”), a food tech company unlocking the natural genetic diversity of plants, announced today that it became one of the first U.S.-based ingredient providers to achieve the international ProTerra Certification, a rigorous global standard that sets the bar for sustainable agricultural practices and labor practices as well as segregated non-GMO programs and more. Benson Hill also joins the respected ProTerra Network, a group of companies dedicated to sustainable practices and continuous improvement.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230118005254/en/
Benson Hill Achieves ProTerra Sustainability Certification for its Proprietary Non-GMO Soy Portfolio. The company is one of the first U.S.-based ingredient providers to verify its sustainable practices under rigorous global standard. (Photo: Business Wire)
The ProTerra Certification program promotes social and environmental sustainability through food and feed supply chains, to support efforts to continuously improve day-to-day business operations and to help organizations to engage and implement the concept of sustainable development.
Throughout an extensive certification process, Benson Hill completed audits of its Creston, Iowa, and Seymour, Ind., plants as well as two shipping ports that store and transport its non-GMO soymeal. Benson Hill also partnered with its growers to conduct several on-farm visits. These in-depth audits examined data related to identity preservation along with deforestation practices, biodiversity efforts, and other Environmental, Social and Governance (ESG) metrics such as fair labor practices.
“I am delighted to welcome Benson Hill as a ProTerra Network Member. This certification demonstrates their engagement to continuously improve agricultural practices and achieve full transparency in the food supply chain,” said Emese van Maanen, Managing Director for the ProTerra Foundation. “Collaboration with farmers is essential to developing long-term relationships that create benefits from plant to plate.”
“Through our journey with ProTerra we gained important insights to solidify our position as a global ingredients company focused on responsible growth,” said Andres Martin, Executive Vice President and General Manager, International for Benson Hill. “Achieving the ProTerra certification standard is a testament to the ESG principles guiding our work to sustainably deliver our non-GMO soybean portfolio to markets within and outside the United States.”
The ProTerra standard, against which organizations are certified, is based on the Basel Criteria for Responsible Soy (created by Coop Switzerland and World Wildlife Fund). Today the standard is applicable to all sectors of the food and agricultural system worldwide and at all stages of the food chain. In addition, ProTerra certification ensures that high quality supplies of crops, food, and feed, that are independently certified as non-GMO and produced with improved sustainability, are available on the global market. Benson Hill’s proprietary soy ingredient portfolio, designed to meet specific end uses with less processing and increased traceability, is currently available in North America and in Europe.
Benson Hill built its closed-loop business model on sustainable design and systems thinking, which means its products deliver benefits across the entire value chain, from seed to plate. For example, CleanCRUSH™ ingredients derived from the company’s proprietary soybean genetics are designed as a less-processed alternative to commodity soy protein concentrate (SPC). CleanCRUSH ingredients can also reduce the need for costly energy- and water-intensive protein concentrating steps traditionally required for plant-based protein and aquaculture feed applications. In SPC comparisons, this can result in up to a 50 to 90 percent reduction in CO2e, depending on the ingredient source, and up to a 70 percent reduction in water usage.
For more information about Benson Hill’s progress in assessing impact and setting the pace of innovation in food, download its inaugural Environmental, Social and Governance (ESG) Report released in July 2022.
About Benson Hill
Benson Hill moves food forward with the CropOS® platform, a cutting-edge food innovation engine that combines data science and machine learning with biology and genetics. Benson Hill empowers innovators to unlock nature’s genetic diversity from plant to plate, with the purpose of creating nutritious, great-tasting food and ingredient options that are both widely accessible and sustainable. More information can be found at bensonhill.com or on Twitter at @bensonhillinc.
About ProTerra Foundation
The ProTerra Foundation is a not-for-profit organization located in the Netherlands that advances and promotes sustainability at all levels of the feed and food production system. Its mission is to be a global network of businesses supporting more sustainable agricultural practices in the agribusiness supply chains. The ProTerra Standard has been developed to promote social and environmental sustainability through the food and feed supply chains, to support stakeholders in their efforts to continuously improve their day-to-day business and to help organizations in engaging and implementing the concept of sustainable development. For details, please visit www.proterrafoundation.org.
Cautionary Note Regarding Forward-Looking Statements
Certain statements in this press release may be considered “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements generally relate to future events or the Company’s future financial or operating performance and may be identified by words such as “may,” “should,” “expect,” “intend,” “will,” “estimate,” “anticipate,” “believe,” “predict,” or similar words. These forward-looking statements are based upon assumptions made by the Company as of the date hereof and are subject to risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements include, among other things, statements regarding: the anticipated benefits of the Company’s ProTerra certification, ongoing sustainability and ESG initiatives, and farmer collaborations; the Company’s plans to promote sustainable agricultural practices and enhanced food supply chain transparency; anticipated advantages of the Company’s CleanCRUSH ingredients, including expectations regarding reduced carbon emissions and water usage; industry conditions and trends; the Company’s strategy and plans for growth; the expected future performance of and demand for the Company’s products; the Company’s ability to manage, develop and sustainably deliver its products to domestic and international markets; expectations about the markets in which the Company participates; and statements regarding the Company’s competitive positioning, resources, capabilities, and expectations for future performance. Factors that may cause actual results to differ materially from current expectations include, but are not limited to, risks associated with: the Company’s ability to realize the expected benefits of its ProTerra certification and to maintain its ProTerra certification; the Company’s ability to realize benefits associated with its ongoing sustainability and ESG initiatives and farmer collaborations; the success of the Company’s products and their ability to achieve expected results, including results related to sustainability benefits; the Company’s ability to grow and achieve growth profitably; the Company’s ability to maintain relationships with its customers, suppliers and strategic partners; changing industry conditions and consumer preferences; the Company’s ability to retain key personnel and generally execute on its business strategy; global and regional economic, agricultural, financial and commodities markets; political, social and health conditions, both domestically and internationally; the Company’s transition to becoming a public company; the effectiveness of the Company’s risk management strategies; and other risks and uncertainties set forth in the sections entitled “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements” in our filings with the Securities and Exchange Commission (“SEC”), which are available on the SEC’s website at www.sec.gov. We expressly disclaim any duty to update these forward-looking statements, except as otherwise required by law.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230118005254/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
